18F-Positron Emitting/Trimethine Cyanine-Fluorescent Contrast for Image-Guided Prostate Cancer Management

Harikrishna Kommidi; Hua Guo; Fuad Nurili; Yogindra Vedvyas; Moonsoo M. Jin; Timothy D. McClure; Behfar Ehdaie; Haluk B. Sayman; Oguz Akin; Omer Aras; Richard Ting

doi:10.1021/acs.jmedchem.8b00240

¹⁸F-Positron Emitting/Trimethine Cyanine-Fluorescent Contrast for Image-Guided Prostate Cancer Management

Harikrishna Kommidi, Hua Guo, Fuad Nurili, Yogindra Vedvyas, Moonsoo M. Jin, Timothy D. McClure, Behfar Ehdaie, Haluk B. Sayman, Oguz Akin, Omer Aras, Richard Ting

Research output: Contribution to journal › Article › peer-review

37 Scopus citations

Abstract

[^18/19F]-4, an anionic GCPII/PSMA inhibitor for image-guided intervention in prostate cancer, is described. [¹⁹F]-4 is radiolabeled with a radiochemical yield that is ≥27% and a molar activity of 190 ± 50 mCi/μmol in a <1 h, one-step, aqueous isotopic exchange reaction. [¹⁹F]-4 allows PSMA expression to be imaged by fluorescence (FL) and [¹⁸F]-PET. PC3-PIP (PSMA-positive, EC₅₀ = 6.74 ± 1.33 nM) cancers are specifically delineated in mice that bear 3 million (18 mg) PC3-PIP and PC3 (control, PSMA-negative) cells. Colocalization of [^18/19F]-4 PET, fluorescence, scintillated biodistribution, and PSMA expression are observed.

Original language	English (US)
Pages (from-to)	4256-4262
Number of pages	7
Journal	Journal of Medicinal Chemistry
Volume	61
Issue number	9
DOIs	https://doi.org/10.1021/acs.jmedchem.8b00240
State	Published - May 10 2018

ASJC Scopus subject areas

Molecular Medicine
Drug Discovery

Access to Document

10.1021/acs.jmedchem.8b00240

Cite this

@article{27302a388ed145af98f02af8a07ac834,

title = "18F-Positron Emitting/Trimethine Cyanine-Fluorescent Contrast for Image-Guided Prostate Cancer Management",

abstract = "[18/19F]-4, an anionic GCPII/PSMA inhibitor for image-guided intervention in prostate cancer, is described. [19F]-4 is radiolabeled with a radiochemical yield that is ≥27% and a molar activity of 190 ± 50 mCi/μmol in a <1 h, one-step, aqueous isotopic exchange reaction. [19F]-4 allows PSMA expression to be imaged by fluorescence (FL) and [18F]-PET. PC3-PIP (PSMA-positive, EC50 = 6.74 ± 1.33 nM) cancers are specifically delineated in mice that bear 3 million (18 mg) PC3-PIP and PC3 (control, PSMA-negative) cells. Colocalization of [18/19F]-4 PET, fluorescence, scintillated biodistribution, and PSMA expression are observed.",

author = "Harikrishna Kommidi and Hua Guo and Fuad Nurili and Yogindra Vedvyas and Jin, {Moonsoo M.} and McClure, {Timothy D.} and Behfar Ehdaie and Sayman, {Haluk B.} and Oguz Akin and Omer Aras and Richard Ting",

note = "Funding Information: The project was supported by National Institutes of Health Grants EB013904, R01CA178007, and P30CA008748. Publisher Copyright: {\textcopyright} 2018 American Chemical Society.",

year = "2018",

month = may,

day = "10",

doi = "10.1021/acs.jmedchem.8b00240",

language = "English (US)",

volume = "61",

pages = "4256--4262",

journal = "Journal of Medicinal Chemistry",

issn = "0022-2623",

publisher = "American Chemical Society",

number = "9",

}

TY - JOUR

T1 - 18F-Positron Emitting/Trimethine Cyanine-Fluorescent Contrast for Image-Guided Prostate Cancer Management

AU - Kommidi, Harikrishna

AU - Guo, Hua

AU - Nurili, Fuad

AU - Vedvyas, Yogindra

AU - Jin, Moonsoo M.

AU - McClure, Timothy D.

AU - Ehdaie, Behfar

AU - Sayman, Haluk B.

AU - Akin, Oguz

AU - Aras, Omer

AU - Ting, Richard

PY - 2018/5/10

Y1 - 2018/5/10

N2 - [18/19F]-4, an anionic GCPII/PSMA inhibitor for image-guided intervention in prostate cancer, is described. [19F]-4 is radiolabeled with a radiochemical yield that is ≥27% and a molar activity of 190 ± 50 mCi/μmol in a <1 h, one-step, aqueous isotopic exchange reaction. [19F]-4 allows PSMA expression to be imaged by fluorescence (FL) and [18F]-PET. PC3-PIP (PSMA-positive, EC50 = 6.74 ± 1.33 nM) cancers are specifically delineated in mice that bear 3 million (18 mg) PC3-PIP and PC3 (control, PSMA-negative) cells. Colocalization of [18/19F]-4 PET, fluorescence, scintillated biodistribution, and PSMA expression are observed.

AB - [18/19F]-4, an anionic GCPII/PSMA inhibitor for image-guided intervention in prostate cancer, is described. [19F]-4 is radiolabeled with a radiochemical yield that is ≥27% and a molar activity of 190 ± 50 mCi/μmol in a <1 h, one-step, aqueous isotopic exchange reaction. [19F]-4 allows PSMA expression to be imaged by fluorescence (FL) and [18F]-PET. PC3-PIP (PSMA-positive, EC50 = 6.74 ± 1.33 nM) cancers are specifically delineated in mice that bear 3 million (18 mg) PC3-PIP and PC3 (control, PSMA-negative) cells. Colocalization of [18/19F]-4 PET, fluorescence, scintillated biodistribution, and PSMA expression are observed.

UR - http://www.scopus.com/inward/record.url?scp=85046786143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046786143&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.8b00240

DO - 10.1021/acs.jmedchem.8b00240

M3 - Article

C2 - 29676909

AN - SCOPUS:85046786143

VL - 61

SP - 4256

EP - 4262

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 9

ER -

¹⁸F-Positron Emitting/Trimethine Cyanine-Fluorescent Contrast for Image-Guided Prostate Cancer Management

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this